Ironwood Pharmaceuticals (IRWD) Non Operating Interest Expenses (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Non Operating Interest Expenses across 17 years of filings, most recently posting $7.2 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses fell 13.8% year-over-year to $7.2 million; the TTM figure through Jun 2026 stood at $32.7 million (down 6.03% YoY), while the FY2025 annual figure was $32.7 million, down 0.87% from the prior year.
• Non Operating Interest Expenses came in at $7.2 million for Q2 2026 at Ironwood Pharmaceuticals, down from $9.1 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $9.8 million in Q3 2023 to a low of $1.5 million in Q3 2022.
• Average Non Operating Interest Expenses over 5 years is $6.2 million, with a median of $7.7 million recorded in 2024.
• Year-over-year, Non Operating Interest Expenses plunged 80.81% in 2022 and surged 545.6% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at $1.5 million in 2022, then soared by 451.97% to $8.4 million in 2023, then gained by 5.83% to $8.9 million in 2024, then fell by 11.53% to $7.9 million in 2025, then decreased by 8.66% to $7.2 million in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $7.2 million in Q2 2026, $9.1 million in Q1 2026, and $7.9 million in Q4 2025.